The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
The efficacy advantage of evolocumab (AMG 145) dosed at 140 mg every 2 weeks versus 420 mg every 4 weeks in patients with hypercholesterolemia: Evidence from a meta-analysis
复制标题
对于高胆固醇血症患者，每 2 周 140 mg 剂量的 evolocumab (AMG 145) 与每 4 周 420 mg 剂量的疗效优势：来自荟萃分析的证据
DOI：
10.1016/j.ejim.2016.10.009
复制
发表时间：
2017-03-01
影响因子：
8
通讯作者：
Liu, Cheng-Yun
中科院分区：
文献类型：
--
作者：
He, Xiao-Xiao;Zhang, Rong;Liu, Cheng-Yun
背景：依洛尤单抗（AMG 145）作为一种前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂，已被证实可降低低密度脂蛋白胆固醇（LDL - C）水平。每2周（Q2W）给药140毫克以及每4周（Q4W）给药420毫克的剂量被广泛应用，且这两种给药方案在临床试验中均有效。然而，一些研究人员推测，每2周给药140毫克的方案疗效相当甚至更佳。本项荟萃分析旨在评估这两种剂量在疗效和安全性方面的差异。
方法：我们检索了PubMed、EMBASE和Web of Science数据库，以确定2016年1月之前发表的相关临床试验。共确定了来自8项随机对照试验的2403名患者，并将其纳入分析。
结果：每2周给药140毫克的依洛尤单抗治疗使LDL - C浓度较基线的百分比变化更大（-7.27；95%置信区间（CI）为 -10.36至 -4.18），并且在实现LDL - C治疗目标方面疗效更佳 。
Background: Evolocumab (AMG 145), a PCSK9 inhibitor, has been shown to decrease low-density lipoprotein cholesterol (LDL-C) levels. Doses of 140 mg administered every 2 weeks (Q2W) and 420 mg administered every 4 weeks (Q4W) are widely used, and both dosing schedules were effective in clinical trials. However, some researchers have speculated that 140 mg Q2W administration has equal or even greater efficacy. This meta-analysis was performed to assess the differences in efficacy and safety between the two doses.Methods: We searched the PubMed, EMBASE, and Web of Science databases to identify relevant clinical trials published before January 2016. A total of 2403 patients from 8 randomized controlled trials were identified and included in the analysis.Results: Evolocumab administered at 140 mg Q2W resulted in a greater percent change from baseline in LDL-C concentration (-7.27; 95% confidence interval (CI), -10.36 to -4.18) and had greater efficacy in achieving the treatment goal of LDL-C